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Alterations of CYP3A4 and P-glycoprotein activity in vivo with
time in renal graft recipients.
Background. Catabolism by intestinal and hepatic
cytochrome P450 3A4 (CYP3A4), and excretion by P-
glycoprotein (PGP), has a major influence on oral bioavail-
ability of calcineurin inhibitors. In this study, the activity
of intestinal and hepatic CYP3A4 and PGP in vivo was
assessed in renal transplant recipients during the first year after
transplantation (Tx).
Methods. Stable Caucasian renal transplant patients were
tested at 1 week, 3 months, and 1 year after Tx, and compared
with the results obtained in drug-free healthy volunteers. In-
testinal and hepatic CYP3A4 and PGP activity were determined
by measurement of 14C-excretion dynamics in breath and urine
after oral and intravenous administration of [N-methyl-14C]-
erythromycin.
Results. Compared with 1 week after Tx, intestinal and hep-
atic CYP3A4 activity significantly decreased at 3 months and
1 year after Tx (−33% and −45%; −7% and −33%, respec-
tively). Compared with the healthy volunteers, intestinal and
hepatic CYP3A4 activity of the patients was significantly in-
creased at 1 week after Tx, but normalized at 1 year after Tx.
A similar pattern, though not significant, was seen for intestinal
PGP activity.
Conclusion. Phenotypic expression of hepatic and intestinal
CYP3A4 was increased immediately after Tx, but gradually de-
creased to basal levels toward the end of the first year after
Tx. The most plausible explanation for this evolution was the
tapering of corticosteroid (CS) doses. These findings may also
explain the increasing bioavailability of tacrolimus with time
after Tx.
Immunosuppressants such as the calcineurin inhibi-
tors, cyclosporine A, tacrolimus (FK 506), and sirolimus,
are cornerstones in the maintenance therapy of clini-
cal organ transplantation (Tx). Oral bioavailability of
these drugs is strongly influenced by cytochrome P450
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3A4 (CYP3A4)-mediated catabolism and P-glycoprotein
(PGP)-mediated active drug efflux. The activity of both
elimination pathways is characterized by substantial in-
trasubject and intersubject variability, necessitating in-
tense drug monitoring and drug adjustment to prevent
both rejection and toxicity.
To date, little is known about the in vivo activity of
hepatic and intestinal CYP3A4/PGP in graft recipients,
and whether this activity changes with time after Tx. Ret-
rospective analyses of clinical data obtained in renal Tx
patients showed an increase of dose normalized trough
levels of FK506 during the first year after Tx, and thus, in-
directly suggest an evolution toward decreased activities
[1–2]. Only for hepatic CYP3A4, in vivo measurements
have confirmed this hypothesis [3].
The aim of this study was to evaluate evolution of hep-
atic and intestinal CYP3A4 and PGP activity as a func-
tion of time during the first year after renal Tx. This was
done by employing a recently developed and validated
noninvasive breath and urine test, using [N-methyl-14C]-
erythromycin as CYP3A4 and PGP probe in vivo. Briefly,
the recovery of 14CO2 in breath reflects the oxidative
demethylation rate of the tracer by CYP3A4 activity.
14C recovery in urine represents the fraction of absorbed
tracer not eliminated by hepatic or intestinal PGP, or hep-
atic or intestinal CYP3A4. By combining the iv and po ad-
ministration of [N-methyl-14C]-erythromycin, and using
deconvolution mathematics, both hepatic and intestinal
CYP3A4 and PGP activity can be measured in humans
[4].
METHODS
Subjects
Thirteen Caucasian renal transplant patients were
studied in 3 different conditions. Patients with a known
history of gastrointestinal or hepatic diseases, or with
previous gastrointestinal surgery, were excluded. All
but one patient received a cadaveric graft; none were
multiple organ recipients. Transplantation surgery went
uneventfully, and there was no delayed graft function or
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Table 1. Patient demographics during first year after transplantation
1 week 3 months 1 year
after Tx after Tx after Tx
Sex M/F 10/3 10/3 10/3
Weight kg 71 (62–78) 74 (62–80) 79 (63–82)
S-creat mg/dL 1.77 (1.44–2.08) 1.72 (1.55–1.95) 1.44 (1.33–1.8)
Creat clearance 49 (32–61) 50 (45–62) 54 (53–75)
mL/min
Hematocrita 0.34 (0.31–0.36) 0.35 (0.32–0.40) 42 (0.39–0.45)
Albumin g/La 33 (31–36) 41 (40–42) 43 (41–45)
Bilirubin mg/dL 0.4 (0.3–0.6) 0.4 (0.4–0.6) 0.4 (0.4–0.6)
CS dose mg/da 20 4 2.5 (2–4)
MMF dose g/d 1 1 1
FK 506 dose 10 (6–12) 9 (8–10) 5.5 (3–7.5)
mg/da
FK 506 trough 15 (13–16) 11 (10–14) 10.5 (10–13)
ng/La
BAIb 11 (6–14) 10 (8–13) 17 (12–22)
Abbreviations are: CS, corticosteroids; MMF, mycophenolate mofetil; FK
506, tacrolimus; BAI, bioavailability index (=FK 506 trough (ng/L)/FK 506 dose
(mg/kg) ratio, multiplied by 100). For each continuous variable, median and (in-
terquartile range ) is given.
aP < 0.05 by mixed linear models ANOVA.
bP = 0.06 by mixed linear models ANOVA.
acute rejection in any patient. The immunosuppressive
regimen consisted of CS, FK 506, and mofetil mycophe-
nolate (MMF) in all. More specifically, an induction dose
of 500 mg methylprednisolone intravenous (iv) was given
at day 0, followed by 40 mg iv the next day. At day 2 to
10 the dose was 16 mg per oral (po), after which it was
gradually tapered to reach a dose of 4 mg/day at day 90. In
5 patients this dose was maintained until 1 year after Tx,
in 7, further tapering to 2 mg/day took place, and in 1 pa-
tient, CS were completely stopped. FK 506 was started at
0.2 mg/kg/day before Tx, and thereafter adjusted to ob-
tain blood trough levels of 10 to 15 lg/L. The dose of MMF
was set at 1 g a day for all patients. Demographic data
are presented in Table 1. Concomitant medication did
not change during the first three months after Tx in any
patient. At 3 months after Tx, CMV (cytomegalovirus)
prophylaxis with ganciclovir (Cymevene, Roche, Basel,
Switzerland; started when donor or recipient were CMV
antibody positive) and PC (Pneumocystis carinii) prophy-
laxis with trimetoprim-sulfametoxazole (Bactrim Forte,
Roche) were stopped in all patients. All patients had an
uneventful clinical course during the first year after Tx
except one patient, who developed polyoma infection of
the graft with progressive decrease of graft function. In
addition, 27 Caucasian nonsmoking and drug free healthy
controls underwent the same test protocol. All subjects
adhered to a sodium restricted (≤6 g/24 h), and other-
wise standard western diet, not containing grapefruit or
other related citrus fruits or their juices; in addition, the
use of any herbal remedies, such as St. John’s wort, was
prohibited.
The Ethical Committee of the University of Leuven
approved the study protocol. Written informed consent
was obtained from all subjects.
Materials and measurements
All tests were performed after an overnight fast and
while the subjects were seated. In the iv 14C-erythromycin
breath and urine test (iv EBT + EUT), 74 kBq of [N-
methyl-14C]-erythromycin (NEN Life Science Products,
Inc., Boston, MA, USA) was dissolved in 2 mL saline
0.9% immediately before testing, and injected in bolus
via a 22-lm pore bio filter (Pall Corporation, Ann Arbor,
MI, USA) in a cubital vein. In the po 14C-erythromycin
breath and urine test (po EBT + EUT), 74 kBq of
[N-methyl-14C]-erythromycin was incorporated in a
lactose-containing gelatin capsule (Belgica T.O.P., Turn-
hout, Belgium). The capsule was ingested with 150 mL of
water.
The iv and po EBT + EUT were always performed on
two consecutive days in the same order (first iv, then po)
at 1 week, 3 months, and 1 year after Tx.
For the EBT, breath samples were obtained by exhal-
ing into a scintillation vial containing 2 mmol of hyamine
hydroxide dissolved in 2 mL ethanol in the presence
of thymolphthalein as indicator. Blowing was continued
until the indicator decolorized, corresponding with the
capture of 2 mmol CO2. Breath samples were taken be-
fore the injection/ingestion of tracer, and every 10 min-
utes during 4 hours thereafter.
For the EUT, urine was collected before and at 0.5, 1,
1.5, 2, 4, 6, 8, 12, and 24 hours after injection/ingestion of
the tracer. The volumes were measured and an aliquot
of 3 mL was taken. The subjects were kept fasting until
the breath test was finished, but were stimulated to drink
water (750 mL) to make urine collections more reliable.
Detailed information of the technique used to analyze
samples for 14C recovery has been described in earlier
reports [5]. In short, quantification of 14C in breath and
urine samples was done by liquid scintillation spectrome-
try (Packard Tri-Carb Liquid Scintillation Spectrometer,
model 3375; Packard Instruments, Inc., Downers Grove,
IL, USA).
Calculations
Assuming a stable CO2 production of 300 mmol/m2
body surface area per hour in rest, the amount of 14C
in each sample of breath could be expressed as % dose/h
recovery. By plotting this as a function of time, a % dose/h
recovery rate curve (D) was obtained. Also a cumulative
% dose recovery curve (C) was constructed by means of
the trapezoidal rule.
From the measured amount of 14C in the urine sam-
ples and the volumes of the urine collections, the % dose
recovery for each collection was also calculated and a
cumulative % dose recovery curve (C) was plotted.
For the EBT and EUT, the obtained curves were fitted
according to the least square method by means of Excel-
visual basic software (Microsoft, Seattle, WA, USA) by
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Fig. 1. Median 14C recovery in breath after
intravenous (A) and per oral (B) adminis-
tration of 74 kBq of 14C-erythromycin, and
deconvolution (C) in healthy volunteers (•)
and patients at 1 week (), 3 months (), and
1 year () after Tx. Left: % dose/h recovery
rate curve (D); right: cumulative % dose re-
covery curve (C).
varying the parameters m, k, and b in the following
formulas:
C = m.(1 − e−kt)b
(a) for cumulative dose excretion curves
D = m.k.b.e−kt · (1 − e−kt)b−1
(b) for dose excretion curves,
where t is the time in hours; m equals the total cumulative
14C recovery when time is infinite; k and b determine time
of maximal excretion rate (Tmax), and T1/2 (half-life) as
described before [4–7].
Because hepatic and intestinal mucosal CYP3A4 and
PGP activity are part of a complex multicompartmen-
tal model, in which rate constants for intercompartmen-
tal exchange cannot be explicitly calculated, a previously
reported separation model [4, 7] was used to separate
the hepatic and intestinal CYP3A4 and PGP activity as
isolated functions by means of mathematical deconvolu-
tion. Briefly, the processes involved in the iv and po EBT
and EUT were expressed as the following convolution
products:
iv EBT = HCYP3A4(c)
po EBT = ICYP3A4 × HCYP3A4(d)
iv EUT = (1 − HPGP) × R(e)
po EUT = (1 − IPGP) × (1 − HPGP) × R(f),
in which HCYP3A4 and ICYP3A4 stand for the hepatic
and intestinal demethylation process, respectively; HPGP
stands for the hepatic, and IPGP for the intestinal ex-
cretion process, and R for the renal excretion rate of
absorbed non-CYP3A4 demethylated [N-methyl-14C]-
erythromycin that was also not excreted by hepatic or
intestinal PGP. From equation (c) and (d), intestinal
CYP3A4 catabolic activity can be isolated by applying
the deconvolution technique to the iv and po EBT curves.
The resulting D and C curves represent the percentage
of 14C recovery (rate and total accumulation) in breath
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Table 2. Evolution of hepatic and intestinal CYP3A4 activity during the first year after Tx, assessed by the iv (hepatic) and po + deconvolved
(intestinal) Erythromycin Breath Test
1 week 3 months 1 year
Time after Tx median Q1–Q3 median Q1–Q3 median Q1–Q3 P value
EBT
IV
m 8.58 6.92–10.92 7.96 6.6–10.66 5.69 4.79–5.97 0.013
T1/2 106 95–113 103 96–120 96 87–126 NS
Tmax NA NA NA
PO
m 1.56 1.07–1.94 0.84 0.59–1.48 0.48 0.28–0.67 < 0.001
T1/2 153 126–181 132 111–147 134 115–168 NS
Tmax 87 79–107 78 69–97 79 68–90 NS
Deconvolution
m 16.07 12.12–23.54 11.33 6.9–18.85 8.91 4.86–13.32 0.048
T1/2 37 29–61 35 26–46 29 21–39 NS
Tmax 14 4–21 13 7–42 11 10–12 NS
Abbreviations are: m, the total cumulative 14C recovery when time is infinite; T1/2, half-life; Tmax, time of maximal excretion rate; Q1–Q3, interquartile range; NS,
not significant.
of the fraction of tracer that eventually entered the en-
terocyte, but which had not yet been exposed to hepatic
CYP3A4. Similarly, information on hepatic and intesti-
nal PGP activity can be obtained by application of the
separation model to the iv (e) and po (f) EUT curves.
This results in a curve representing the separated frac-
tion of tracer that was absorbed along the gastrointestinal
tract and escaped excretion by the intestinal PGP system
[4].
For all the obtained curves (po and iv EBT and EUT
and deconvolution) m, T1/2, and Tmax were evaluated.
Statistics
For statistical analysis, SAS software, version 8.02 (SAS
Institute, Cary, NC, USA) was used.
The effect of time after Tx on the patients’ test results
was evaluated using linear mixed models analysis of vari-
ance (ANOVA). To compare the results of healthy vol-
unteers and patients, Wilcoxon’s rank sum test was used.
A P value smaller than 0.05 was considered significant.
RESULTS
Evolution of hepatic and intestinal CYP3A4 activity
The median iv EBT D and C-curves of the patients
at 1 week, 3 months, and 1 year after Tx are shown in
Figure 1A. The shape of the curves was similar, with a
steep ascent and an exponentially descending slope of
the D-curve and gradually raising C-curve. The curves ob-
tained at 1 week and 3 months after Tx are nearly identi-
cal. At 1 year, however, the curves decreased significantly.
Derived curve characteristics m, Tmax, and T1/2 are listed
in Table 2. The results at 1 week and 3 months were
similar, whereas total cumulative 14CO2 recovery (m) at
1 year had dropped with 25% at a significant level, and
was in the same range as for healthy volunteers. Kinet-
ics remained unchanged. This indicates that total hep-
atic CYP3A4 activity decreased during the first year after
Tx.
Figure 1B depicts the po EBT curves. The overall shape
of the curves, with a gradually ascending D-curve, reach-
ing a small peak followed by a slow decline in activity, and
steadily raising C-curve, was similar at all time points. As
for the iv EBT, the magnitude of the curves also declined
significantly in time, but more profoundly, with changes
being already visible from 1 week to 3 months after Tx.
Consequently, derived m values dropped with 43% and
66% from 1 week to 3 months and 1 year after Tx, re-
spectively. Again, kinetic parameters did not change. This
points to an important decrease of intestinal CYP3A4 ac-
tivity starting from 1 week during the first year after Tx.
The separated EBT curves (Fig. 1C), which display
isolated intestinal CYP3A4 activity, had shapes simi-
lar to the D and C-curves of the iv EBT, which did
not clearly change through time. The magnitude of the
curves, though, diminished significantly with time from
the first week after Tx. Subsequently, the derived param-
eter m, reflecting total intestinal CYP3A4 activity, de-
creased with 33% and 50% at 3 months and 1 year after
Tx, respectively.
Evolution of hepatic and intestinal PGP activity
The EUT C-curves, corresponding inversely with PGP
activity, are shown in Figure 2A to C for the iv, po, and
separated EUT, respectively. Table 3 contains the derived
m values and kinetics.
The shape of the iv EUT curve had an extremely sharp
raise during the first hours, rendering derivation of Tmax
impossible, and was followed by a plateau phase. This
pattern did not change significantly with time after Tx,
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Fig. 2. Median cumulative % dose recovery curve (C) in urine after
intravenous (A) and per oral (B) administration of 74 kBq of 14C-
erythromycin, and deconvolution (C) in healthy volunteers (•) and
patients at 1 week (), 3 months (), and 1 year () after Tx.
and neither did the level of the plateau reached. These
observations implicate that hepatic PGP activity re-
mained equal throughout the first year after Tx.
The po EUT curve rose more gradually than the iv
curve, and no definite plateau was reached after 24 hours
of measurement. At 3 months after Tx, 38% more 14C had
accumulated in the urine compared to 1 week after Tx.
At 1 year after Tx, this difference was less pronounced,
with only a 25% raise. The derived m values behaved
in the same way. These changes were not significant. Ki-
netic curve parameters remained unaltered during the
first year after Tx.
The deconvolved EUT curve, displaying isolated in-
testinal PGP activity, was similar in shape at the 3
time points, but reached a higher plateau at 1 year and
3 months compared to 1 week after Tx. The same was
seen for the parameter m. However, this evolution did
not reach statistical significance (P = 0.09). Kinetic pa-
rameters did not differ. These observations suggest that
intestinal PGP activity might decline as a function of time
after Tx.
Comparison with healthy volunteers
The curves (iv, po, and deconvolved) obtained in 27
healthy volunteers are shown in Figure 1A to C and
Figure 2A to C for the EBT and EUT, respectively.
For the EBT, which corresponds directly with CYP3A4
activity, the curves could bearably be distinguished from
those of the patients measured at 1 year post Tx. At
1 week and 3 months after Tx, the iv EBT was significantly
higher in patients compared to healthy volunteers. Re-
sults of the po and deconvolved EBT revealed a similar
difference, which was only significant at 1 week after Tx.
The EUT curves of healthy volunteers and patients at
1 year post Tx also nearly equal each other. The only
difference, although not significant (P = 0.13), was seen
between the deconvolved curves of the volunteers and
those of the patients at 1 week after Tx. This might in-
dicate a stronger intestinal PGP activity in patients at
1 week post Tx.
Figure 3 summarizes relative differences of CYP3A4
and PGP activity in patients at 1 week, 3 months, and
1 year after Tx compared to healthy volunteers, based on
the changes of m values for the iv and po EBT and EUT.
DISCUSSION
In the present study, the phenotypic activity of both in-
testinal and hepatic CYP3A4 and PGP was evaluated as
a function of time during the first year after renal trans-
plantation in humans.
A significantly higher activity of hepatic and intesti-
nal CYP3A4 was noted at the first week after Tx, and
it gradually dropped to more basal levels at 1 year com-
pared with a control group of healthy volunteers. This
evolution was more pronounced for intestinal than for
hepatic CYP3A4 activity. For PGP activity, the observed
data do not allow definite conclusions to be drawn: only
a tendency (P = 0.09) was noted for intestinal PGP to be
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Table 3. Evolution of hepatic and intestinal PGP activity during the first year after Tx, assessed by the iv (hepatic) and po + deconvolved
(intestinal) Erythromycin Urine Test
1 week 3 months 1 year
Time after Tx median Q1–Q3 median Q1–Q3 median Q1–Q3 P value
EUT
IV
m 15.10 12.58–18.83 14.45 12.12–19.55 13.39 10.95–15.56 NS
T1/2 122 93–150 102 94–132 98 69–124 NS
Tmax NA NA NA
PO
m 3.20 2.53–5.05 5.08 4.32–6.36 3.54 3.03–3.88 NS
T1/2 392 286–478 548 411–631 523 468–564 NS
Tmax 113 91–212 255 150–288 293 175–330 NS
Deconvolution
m 21.06 15.5–29.05 31.80 24.54–44.1 32.35 27.48–39.37 0.09
T1/2 174 92–314 323 189–510 245 198–361 NS
Tmax NA NA NA
Abbreviations are: m, the total cumulative 14C recovery when time is infinite; T1/2, half-life; Tmax, time of maximal excretion rate; Q1–Q3, interquartile range; NS,
not significant; NA, not applicable.
more active early after Tx. In addition, this difference in
activity was not as large as for CYP3A4. Hepatic PGP
activity did not change as a function of time after Tx.
At 1 year post Tx, patients had similar PGP activities as
healthy volunteers. Because the main changes in the po
and iv EBT and EUT were observed for the total cu-
mulative 14C recovery, and the kinetics did not change
significantly, the total capacity of CYP3A4 and PGP ac-
tivity, but not the rate, seems to decrease with time after
Tx.
The most plausible explanation for these observations
is the concomitant decrease in CS exposure with time af-
ter Tx, resulting in a diminished induction of CYP3A4
and—possibly—PGP. There are numerous reports that
demonstrated the induction of CYP3A4 and PGP by CS
in vitro [8, 9]. However, these in vitro experiments are
performed in rather unphysiologic conditions with the
use of very high doses (e.g., 8 to 75 mg/kg of dexam-
ethasone). Moreover, the obtained data do not allow the
estimation of the global in vivo effect or the differenti-
ation between hepatic and intestinal CYP3A4/PGP ac-
tivity. There is evidence from in vivo experiments in rats
that high doses of dexamethasone induce both intestinal
and hepatic CYP3A4 and PGP [10], and human hepatic
CYP3A4 activity has been shown to be induced in cancer
patients taking 8 mg of dexamethasone twice a day [11].
These findings suggest that CS might reduce oral bioavail-
ability of calcineurin inhibitors and sirolimus. Some clini-
cal studies corroborate this hypothesis. Two retrospective
analyses of dose and weight normalized through levels
(used as a surrogate marker for true oral bioavailability)
for FK506 show an increase of this marker in function
of time after Tx, paralleling a decrease in CS dose [1,
2]. A recent prospective study of FK506 pharmacokinet-
ics showed that withdrawal of CS resulted in a signifi-
cant increase of area under the concentration-time curve
(AUC), and dose normalized trough levels of FK506
[12].
Furthermore, the observed apparently higher sensi-
tivity of intestinal CYP3A4 to CS mediated induction
is in agreement with a pharmacokinetic study of orally
administered triazolam, used as a CYP3A4 probe [13].
In this study, a 10 days’ course of 8 mg methylpred-
nisolone did only show a significant reduction of the peak
plasma concentration of triazolam, suggesting increased
intestinal CYP3A4 mediated catabolism. Total exposure
and clearance, however, did not alter, indicating that the
given dose failed to induce hepatic CYP3A4 significantly.
The doses in the present study were much higher, and
this explains why an induction of hepatic CYP3A4 was
observed.
However, other factors may also be involved in the
observed evolution of CYP3A4 and PGP activity as a
function of time after Tx. To minimize these factors as
much as possible, only patients without any serious con-
comitant medical diseases or surgical history, and with
an uneventful clinical course during the first week after
Tx, have been included in the study. During the follow-
up period there were no complications, except for one
dropout at 1 year post Tx, as described above. The sur-
gical transplantation team and its procedures (including
anesthesia) and methods used were the same for all pa-
tients. Medical therapy remained unchanged during the
first year after Tx, except for the cessation of PC and
CMV prophylaxis with trimetoprim-sulfametoxazole and
ganciclovir, respectively. These products are not known
as inducers or inhibitors of CYP3A4/PGP. In addition,
the diet (without grapefruit or other citrus fruits known
to have a potential influence on CYP3A4/PGP) did not
change during the observed period and was similar in all
subjects. They were also all of Caucasian race. Another
important issue concerns renal function, which has been
Lemahieu et al: CYP3A4/PGP activity in renal transplantation 439
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parison of m values for iv and deconvoluted EBT and EUT observed
in healthy volunteers (=100%, black), and patients at 1 week after
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shade). ∗P < 0.05 for comparison between the patients on different
time points, by means of mixed linear models ANOVA. #P < 0.05 for
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shown to influence intestinal and hepatic CYP3A4 and
PGP activity as well. End-stage renal disease has been
documented to decrease hepatic CYP3A4 activity in an-
imal models and humans, requiring dialysis [14–15]. For
PGP activity, this has also been demonstrated in rat mod-
els in vivo [16]. However, the patients in the present study
had a functioning renal graft with a clearly improved kid-
ney function from the first week post Tx, remaining stable
and even slightly ameliorating during the following year
(Table 1). Therefore, it seems unlikely that the potential
confounding influence of renal function could explain the
reported results.
Finally, it is notable that, at 1 year after Tx, patients
displayed similar CYP3A4 and PGP activities as healthy
volunteers taking no medication. At that time, all patients
were still taking FK506. FK506 is a known substrate of
CYP3A4/PGP, and has been shown to inhibit these pro-
teins at high concentrations in vitro [17]. Although this
was not the aim of the present study, our findings corrob-
orate the assumption that FK506, at doses used in clinical
transplantation, does not alter CYP3A4 or PGP activity
in vivo [18].
CONCLUSION
It has been demonstrated that intestinal and hepatic
CYP3A4 activity in renal transplant recipients is maxi-
mal early after Tx and gradually decreases during the fol-
lowing months. A similar, but not significant, trend was
noticed for intestinal PGP. This phenomenon is associ-
ated with the reduction of steroid doses with time after
Tx, which strongly suggests that high steroid doses used
as induction immunosuppression therapy after renal Tx
induce CYP3A4 in humans, in accordance with in vitro
and animal model studies. These findings may explain the
increased oral bioavailability of tacrolimus after tapering
or stopping steroids.
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